8H9 Biosimilar - Research Grade

Human

B7-H3 (CD276)

>1mg/ml

Human IgG1 Kappa

Omburtamab Biosimilar - Research Grade (ICH5095), Enoblituzumab Biosimilar - Research Grade (ICH5124), Ifinatamab Biosimilar - Research Grade (ICH5204), Mirzotamab Biosimilar - Research Grade (ICH5687), Vobramitamab Biosimilar - Research Grade (ICH5985)

https://www.imgt.org/mAb-DB/

ICH3002

Q5ZPR3

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-B7-H3 (CD276) antibody 8H9, supplied for research use only. It is built around the human B7-H3 target and formatted as a human IgG1 Kappa recombinant protein, making it a convenient reference reagent for laboratories studying B7-H3 biology and B7-H3-directed antibody development. It is not the clinical drug and is not intended for human or veterinary use. As a research-grade biosimilar it is useful as a positive binding control, an isotype-matched benchmark, a capture or detection reagent, and a comparator in assay development and antibody-engineering workflows (for example, when generating or characterizing B7-H3-targeting antibodies, bispecifics, ADCs, or CAR constructs). The material is offered at low endotoxin (research grade typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities suitable for in-vitro assays, protein-interaction studies, and preclinical models. Because it reproduces the target-binding specificity of the originator without therapeutic intent, it supports reproducible, cost-effective experimentation across binding, neutralization, and functional characterization studies. B7-H3 (CD276) is a type I transmembrane glycoprotein of the B7/CD28 immunoglobulin superfamily. In humans the predominant isoform is a 4Ig form containing tandemly duplicated IgV-IgC domains, while a shorter 2Ig form also occurs; a soluble form can be shed. Although initially described as a costimulatory molecule, B7-H3 is now recognized as predominantly co-inhibitory in T-cell responses and as a modulator of NK-cell activity, contributing to immune evasion. Its counter-receptor(s) remain incompletely defined. B7-H3 is notable for markedly restricted expression on normal tissues but broad, high-level overexpression across many solid tumors and on tumor-associated vasculature and stroma, where it correlates with poor prognosis. This tumor-selective expression makes B7-H3 an attractive target for antibody, bispecific, ADC, radioimmunotherapy, and CAR-based approaches, and underlies interest in antibodies such as 8H9.

4Ig-B7-H3, B7 homolog 3 (B7-H3), CD276, B7H3

Detects human B7-H3 (CD276)

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.